A more recent version of this article appeared on January 1, 2004.
Submitted on September 11, 2003
Revised on October 26, 2003
Accepted on October 30, 2003
From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis
Shi-Jian Ding, Yan Li, Ye-Xiong Tan, Man-Rong Jiang, Bo Tian, Ying-Kun Liu, Xiao-Xia Shao, Sheng-Long Ye, Jia-Rui Wu, Rong Zeng, Hong-Yang Wang, Zhao-You Tang, and Qi-Chang Xia
Research Center for Proteome Analysis, Institute of Biochemistry and Cell Biology, Shanghai, Shanghai 200031
Corresponding Author: dsj{at}sunm.shcnc.ac.cn
To better understand the mechanism underlying the hepatocellular carcinoma (HCC) metastasis and to search potential markers for HCC prognosis, differential proteomic analysis on two well established HCC cell strains with high and low metastatic potentials, MHCC97-H and MHCC97-L, was conducted using two-dimensional gel electrophoresis followed by matrix-assisted laser desorption/time of flight mass spectrometry. Cytokeratin 19 (CK19) was identified and found to be overexpressed in MHCC97-H as compared with MHCC97-L. This result was further confirmed by two-dimensional Western Blot analysis and immunofluorescence assay. Furthermore, one-dimensional Western Blot analysis showed consistently increased CK19 expression in progressively more metastatic cells. Immunohistochemical study on 102 human HCC specimens revealed that more patients in CK19 positive group had overt intrahepatic metastases (satellite nodules, P<0.05; vascular tumor emboli, P<0.001; tumor TNM staging, P<0.001). CK19 fragment CYFRA21-1 levels measured in sera from nude mice model of human HCC metastasis with radioimmunoassay increased in parallel with tumor progression and rose remarkably when pulmonary metastases occurred. The results demonstrated that overexpression of CK19 in HCC cells is related to metastatic behavior. Serum CK19 level might reflect the pathological progression in some HCC and may be a useful marker for predicting tumor metastasis and a therapeutic target for the treatment of HCC patients with metastases.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
X.-R. Yang, Y. Xu, G.-M. Shi, J. Fan, J. Zhou, Y. Ji, H.-C. Sun, S.-J. Qiu, B. Yu, Q. Gao, et al.
Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection
Clin. Cancer Res.,
June 15, 2008;
14(12):
3850 - 3859.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yamashita, M. Forgues, W. Wang, J. W. Kim, Q. Ye, H. Jia, A. Budhu, K. A. Zanetti, Y. Chen, L.-X. Qin, et al.
EpCAM and {alpha}-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
Cancer Res.,
March 1, 2008;
68(5):
1451 - 1461.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-Z. Pang, L.-X. Qin, N. Ren, Z.-Y. Hei, Q.-H. Ye, W.-D. Jia, B.-S. Sun, G.-L. Lin, D.-Y. Liu, Y.-K. Liu, et al.
Loss of Heterozygosity at D8S298 Is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma
Clin. Cancer Res.,
December 15, 2007;
13(24):
7363 - 7369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yamashita, A. Budhu, M. Forgues, and X. W. Wang
Activation of Hepatic Stem Cell Marker EpCAM by Wnt {beta}-Catenin Signaling in Hepatocellular Carcinoma
Cancer Res.,
November 15, 2007;
67(22):
10831 - 10839.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Sun, B. Xing, Y. Sun, X. Du, M. Lu, C. Hao, Z. Lu, W. Mi, S. Wu, H. Wei, et al.
Proteome Analysis of Hepatocellular Carcinoma by Two-dimensional Difference Gel Electrophoresis: Novel Protein Markers in Hepatocellular Carcinoma Tissues
Mol. Cell. Proteomics,
October 1, 2007;
6(10):
1798 - 1808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. O. Alsaad, S. Serra, A. Perren, E. Hsieh, and R. Chetty
CK19 and CD99 Immunoexpression Profile in Goblet Cell (Mucin-Producing Neuroendocrine Tumors) and Classical Carcinoids of the Vermiform Appendix
International Journal of Surgical Pathology,
July 1, 2007;
15(3):
252 - 257.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Li, Y. Hong, Y.-X. Tan, H. Zhou, J.-H. Ai, S.-J. Li, L. Zhang, Q.-C. Xia, J.-R. Wu, H.-Y. Wang, et al.
Accurate Qualitative and Quantitative Proteomic Analysis of Clinical Hepatocellular Carcinoma Using Laser Capture Microdissection Coupled with Isotope-coded Affinity Tag and Two-dimensional Liquid Chromatography Mass Spectrometry
Mol. Cell. Proteomics,
April 1, 2004;
3(4):
399 - 409.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|